Regeneron Pharmaceuticals Uncategorized Contracts & Agreements

53 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
Regeneron Pharmaceuticals
Biotechnology
2025
Restated Amendment Agreement, dated December 30, 2014 and entered into effective as of May 7, 2012, by and between Bayer HealthCare LLC and the Registrant
Regeneron Pharmaceuticals
Biotechnology
2025
Amendment No. 3 to Master Agreement, dated as of August 1, 2024, by and between Regeneron Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc
Regeneron Pharmaceuticals
Biotechnology
2024
Amendment No
Regeneron Pharmaceuticals
Biotechnology
2024
Amendment No. 1 to Master Agreement, dated as of April 10, 2023, by and between the Registrant and Alnylam Pharmaceuticals, Inc
Regeneron Pharmaceuticals
Biotechnology
2023
Project Agreement, dated as of July 6, 2020, by and between the Registrant and Advanced Technology International
Regeneron Pharmaceuticals
Biotechnology
2021
Project Agreement, dated as of July 6, 2020, by and between the Registrant and Advanced Technology International
Regeneron Pharmaceuticals
Biotechnology
2020
Base Agreement, dated as of July 6, 2020, by and between the Registrant and Advanced Technology International
Regeneron Pharmaceuticals
Biotechnology
2020
Amendment to the Amended and Restated Investor Agreement, dated as of May 25, 2020, by and among Regeneron Pharmaceuticals, Inc., Sanofi, Sanofi-Aventis US LLC, and Aventisub LLC
Regeneron Pharmaceuticals
Biotechnology
2020
Second Amendment Agreement, dated December 19, 2019, by and between Bayer HealthCare LLC and the Registrant
Regeneron Pharmaceuticals
Biotechnology
2020
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
Regeneron Pharmaceuticals
Biotechnology
2020
Master Agreement, dated as of April 8, 2019, by and between the Registrant and Alnylam Pharmaceuticals, Inc
Regeneron Pharmaceuticals
Biotechnology
NY
2019
Investor Agreement, dated as of April 8, 2019, by and between the Registrant and Alnylam Pharmaceuticals, Inc
Regeneron Pharmaceuticals
Biotechnology
MA
2019
Letter Agreement, dated as of January 7, 2018, by and among Regeneron Pharmaceuticals, Inc., Sanofi, sanofi-aventis US LLC, Aventis Pharmaceuticals Inc., sanofi-aventis Amrique du...
Regeneron Pharmaceuticals
Biotechnology
2018
CONSENT AND AMENDMENT NO. 1 MEMORANDUM
Regeneron Pharmaceuticals
Biotechnology
2017
VestType
Regeneron Pharmaceuticals
Biotechnology
NY
2016
VestType
Regeneron Pharmaceuticals
Biotechnology
NY
2016
ID: [ ] Notice of Grant of Award 777 Old Saw Mill River Road And Award Agreement Tarrytown, New York 10591 [NAME] Award Number: [ ] [ADDRESS] Plan: [ ]
Regeneron Pharmaceuticals
Biotechnology
2015
Vest Type
Regeneron Pharmaceuticals
Biotechnology
NY
2015
Vest Type
Regeneron Pharmaceuticals
Biotechnology
NY
2015
Annex A Unwind Period PriceAmendment Payment Amount per Warrant$370.00$273.46$375.00$278.44$380.00$283.43$385.00$288.41$390.00$293.40$395.00$298.38$397.75$301.07
Regeneron Pharmaceuticals
Biotechnology
NY
2015
RESTATED AMENDMENT AGREEMENT
Regeneron Pharmaceuticals
Biotechnology
2015
Amendment, dated as of May 16, 2014, to the Master Terms and Conditions for Warrants, dated as of October 18, 2011, as supplemented by a confirmation dated October 18, 2011,...
Regeneron Pharmaceuticals
Biotechnology
NY
2014
Amendment, dated as of May 15, 2014, to the Master Terms and Conditions for Warrants, dated as of October 18, 2011, as supplemented by a confirmation dated October 18, 2011,...
Regeneron Pharmaceuticals
Biotechnology
NY
2014
Amendment, dated as of May 13, 2014, to the Master Terms and Conditions for Warrants, dated as of October 18, 2011, as supplemented by a confirmation dated October 18, 2011,...
Regeneron Pharmaceuticals
Biotechnology
NY
2014
AMENDED AND RESTATED INVESTOR AGREEMENT By and Among SANOFI, SANOFI-AVENTIS US LLC, AVENTIS PHARMACEUTICALS INC., SANOFI-AVENTIS AMÉRIQUE DU NORD AND REGENERONPHARMACEUTICALS,...
Regeneron Pharmaceuticals
Biotechnology
DE
2014
Annexe 1
Regeneron Pharmaceuticals
Biotechnology
2013
[SANOFI LETTERHEAD]
Regeneron Pharmaceuticals
Biotechnology
2013
AMENDMENT AGREEMENT
Regeneron Pharmaceuticals
Biotechnology
2012
MASTER TERMS AND CONDITIONS FOR BASE ADDITIONALWARRANTS ISSUED BY REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals
Biotechnology
NY
2011
MASTER TERMS AND CONDITIONS FOR CONVERTIBLE BONDHEDGING TRANSACTIONS BETWEEN MORGAN STANLEY & CO. INTERNATIONAL PLC AND REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals
Biotechnology
NY
2011
MASTER TERMS AND CONDITIONS FOR BASE WARRANTS ISSUED BY REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals
Biotechnology
NY
2011
MASTER TERMS AND CONDITIONS FOR BASE WARRANTS ISSUED BY REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals
Biotechnology
NY
2011
MASTER TERMS AND CONDITIONS FOR CONVERTIBLE BONDHEDGING TRANSACTIONS BETWEEN CITIBANK, N.A. AND REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals
Biotechnology
NY
2011
MASTER TERMS AND CONDITIONS FOR BASE WARRANTS ISSUED BY REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals
Biotechnology
NY
2011
MASTER TERMS AND CONDITIONS FOR CONVERTIBLE BONDHEDGING TRANSACTIONS BETWEEN GOLDMAN, SACHS & CO. AND REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals
Biotechnology
NY
2011
SIXTH AMENDMENT TOLEASE
Regeneron Pharmaceuticals
Biotechnology
2010
First Amendment to the InvestorAgreement dated as of December 20, 2007
Regeneron Pharmaceuticals
Biotechnology
2010
THIRD AMENDMENT TOLEASE
Regeneron Pharmaceuticals
Biotechnology
NY
2009
REGENERON PHARMACEUTICALS,INC. OPTION AGREEMENT PURSUANT TO THE 2000 LONG-TERMINCENTIVE PLAN
Regeneron Pharmaceuticals
Biotechnology
NY
2009